Search
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnBinding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.
Categories: HCV Replication Complex InhibitorsSumatriptan
go.drugbank.com/drugs/DB00669ApprovedInvestigationalSumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines. Sumatriptan was granted F...
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalNedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.
Cedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigationalMyelodysplastic syndromes (MDS) are a group of hematopoietic neoplasms that give rise to variable cytopenias progressing to secondary acute myeloid leukemia (sAML), which is invariably fatal if untreated. Hypomethylating agents such as d...
Calcium ascorbate
go.drugbank.com/drugs/DB14483ApprovedNutraceuticalMixtures: Cavan One, Nestabs ONEProducts: Now Ester-C ComplexART5803
go.drugbank.com/drugs/DB18379InvestigationalART5803 is a humanized one-armed monoclonal antibody with a high affinity for the NMDA receptor.
Romiplostim
go.drugbank.com/drugs/DB05332ApprovedInvestigationalThe peptibody molecule has two identical single-chain subunits, each one is made up of 269 amino acid residues.
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedOne study in 1976 demonstrated that metrizoic acid, when used for cardiac angiography, was well tolerated.
Eszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigationalOne major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...